BC Innovations | Dec 11, 2018
Distillery Therapeutics

Inflammation

INDICATION: Inflammatory disease Cell culture studies suggest combined inhibition of BRD4 and HDAC could help treat type I interferon-driven diseases. In fibroblasts from patients deficient in the type I interferon regulators ISG15 or USP18, a...
BC Innovations | Oct 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Sep 26, 2018
Distillery Therapeutics

Cancer

INDICATION: Head and neck cancer In vitro and cell culture studies identified a depsipeptide-based covalent KLK6 inhibitor that could help treat head and neck cancer. High throughput screening of a library of 80,000 small molecules,...
BC Innovations | Sep 20, 2018
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture studies identified an inhibitor of Q209L-mutant Gα-q that could help treat uveal melanoma harboring the mutation. In HEK cell-based signaling and activity assays, a previously reported cyclic depsipeptide-based inhibitor of Gα-q...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
BC Innovations | Aug 9, 2017
Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; breast cancer Patient sample, cell culture and mouse studies suggest inhibiting HDAC1 alone or in combination with T cell therapies could help treat NANOG -positive cervical and breast cancers. In cervical cancer...
BioCentury | May 12, 2017
Product Development

Stepwise to a cure

Phase IIa data for ABX464 from Abivax S.A.S. are a step in the right direction toward a functional cure, but the company will need to show the therapy can achieve much greater reductions in HIV...
BC Innovations | Feb 2, 2017
Strategy

Cure cash

With the goal now to clear rather than just suppress HIV, Gilead Sciences Inc. is using a $22 million grant program to back the scientific strategies it thinks are most likely to empty the HIV...
BC Week In Review | Jan 4, 2016
Clinical News

Vacc-4x: Additional Phase I/II data

Data from 17 evaluable patients with HIV-1 infection in Part B of the open-label, Danish Phase I/II REDUC trial showed that Vacc-4x plus GM-CSF adjuvant followed by 5 mg/m 2 IV Istodax romidepsin -- a...
BC Extra | Dec 22, 2015
Clinical News

Bionor reports latent HIV reservoir reductions

Bionor Pharma ASA (OSE:BIONOR) said its Vacc-4x in combination with cancer drug Istodax romidepsin significantly reduced latent HIV reservoirs among patients in Part B of the Danish Phase I/II REDUC trial. Viral load remained below...
Items per page:
1 - 10 of 155